TL;DR: Peritonectomy procedures are surgical procedures designed to treat peritoneal surface malignancy. They involve resecting or stripping cancer from all intra-abdominal surfaces.
Abstract: New surgical procedures designed to assist in the treatment of peritoneal surface malignancy were sought.Decisions regarding the treatment of cancer depend on the anatomic location of the malignancy and the biologic aggressiveness of the disease. Some patients may have isolated intra-abdominal seeding of malignancy of limited extent or of low biologic grade. In the past, these clinical situations have been regarded as lethal.The cytoreductive approach may require six peritonectomy procedures to resect or strip cancer from all intra-abdominal surfaces.These are greater omentectomy-splenectomy; left upper quadrant peritonectomy; right upper quadrant peritonectomy; lesser omentectomy-cholecystectomy with stripping of the omental bursa; pelvic peritonectomy with sleeve resection of the sigmoid colon; and antrectomy.Peritonectomy procedures and preparation of the abdomen for early postoperative intraperitoneal chemotherapy were described. The author has used the cytoreductive approach to achieve long-term, disease-free survival in selected patients with peritoneal carcinomatosis, peritoneal sarcomatosis or mesothelioma.
TL;DR: The greater omentum was once thought of as a useless, large, mesenterial fold, often getting in the way of surgeons during abdominal intervention and forming troublesome intra-abdominal adhesions.
Abstract: The greater omentum was once thought of as a useless, large, mesenterial fold, often getting in the way of surgeons during abdominal intervention and forming troublesome intra-abdominal adhesions. Resection of the fold has no consequence. Omentectomy was performed carelessly in the past, but does this Cinderella of anatomic and surgical knowledge have value?
TL;DR: It is demonstrated that decreasing VAT through omentectomy, alone or in combination with RYGB surgery, does not improve metabolic function in obese patients.
TL;DR: Improvement in HGP may influence diabetes remission early after Roux-en-Y gastric bypass, and Hepatic insulin sensitivity improved at 1 month after RYGB and was more pronounced in patients with diabetes.
Abstract: OBJECTIVE Early after Roux-en-Y gastric bypass (RYGB), there is improvement in type 2 diabetes, which is characterized by insulin resistance. We determined the acute effects of RYGB, with and without omentectomy, on hepatic and peripheral insulin sensitivity. We also investigated whether preoperative diabetes or postoperative diabetes remission influenced tissue-specific insulin sensitivity after RYGB. RESEARCH DESIGN AND METHODS We studied 40 obese (BMI 48 ± 8 kg/m 2 ) participants, 17 with diabetes. Participants were randomized to RYGB alone or in conjunction with omentectomy. Hyperinsulinemic-euglycemic clamps with isotopic-tracer infusion were completed at baseline and at 1 month postoperatively to assess insulin sensitivity. RESULTS Participants lost 11 ± 4% of body weight at 1 month after RYGB, without an improvement in peripheral insulin sensitivity; these outcomes were not affected by omentectomy, preoperative diabetes, or remission of diabetes. Hepatic glucose production (HGP) and the hepatic insulin sensitivity index improved in all subjects, irrespective of omentectomy ( P ≤ 0.001). Participants with diabetes had higher baseline HGP values ( P = 0.003) that improved to a greater extent after RYGB ( P = 0.006). Of the 17 participants with diabetes, 10 (59%) had remission at 1 month. Diabetes remission had a group × time effect ( P = 0.041) on HGP; those with diabetes remission had lower preoperative and postoperative HGP. CONCLUSIONS Peripheral insulin sensitivity did not improve 1 month after RYGB, irrespective of omentectomy, diabetes, or diabetes remission. Hepatic insulin sensitivity improved at 1 month after RYGB and was more pronounced in patients with diabetes. Improvement in HGP may influence diabetes remission early after RYGB.
TL;DR: The experience with a subset of 30 patients with Stage III or Stage IV ovarian cancer who presented at initial laparotomy with advanced disease in whom large (greater than 10 cm) confluent nodules, plaques, or nodal metastatic deposits were found intraperitoneally is provided.